Henry Querfurth, MD
Neurology · Brighton, MANPI 1336135649
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,244 of the $1,420 with a category attached, or 87.6%. 17 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 37.4% of the total. Reporting peaked in 2019 at $904 and has fallen 83.7% since, to $147 in 2025.
Across 53 payments — averaging $26.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$532
- Teva Pharmaceuticals USA, Inc.$205
- Eisai Inc.$119
- Biohaven Pharmaceuticals, Inc.$97
- UCB, Inc.$90
- Biogen$68
- plus $310 from 11 others
Across 10 payments — averaging $22,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$168K
- Eli Lilly$54K
What the payments were for
- Speaking & faculty fees$564%
- Food & beverage$1,24488%
- Education$1218%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 23 | $532 |
| Teva Pharmaceuticals USA, Inc. | 7 | $205 |
| Eisai Inc. | 1 | $119 |
| Biohaven Pharmaceuticals, Inc. | 1 | $97 |
| UCB, Inc. | 3 | $90 |
| Biogen | 2 | $68 |
| Acorda Therapeutics, Inc | 4 | $56 |
| Portola Pharmaceuticals, LLC | 2 | $52 |
| Avanir Pharmaceuticals, Inc. | 2 | $35 |
| AbbVie | 1 | $28 |
| Johnson & Johnson | 1 | $27 |
| Boston Scientific | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Pfizer | 1 | $20 |
| GE HealthCare | 1 | $19 |
| EMD Serono, Inc. | 1 | $17 |
| SK Life Science, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$119
How this compares
$1,420 in reported general payments places this provider in the 60th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 11 | $55,713 |
| UbrelvyUbrogepant | 20 | $21,267 |
| RexultiBrexpiprazole | 11 | $18,142 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $11,282 |
| Rivastigmine | 45 | $7,700 |
| Galantamine ErGalantamine Hbr | 90 | $6,330 |
| Memantine Hcl ErMemantine Hcl | 87 | $4,665 |
| Donepezil Hcl | 269 | $2,750 |
| Memantine Hcl | 30 | $1,927 |
| Pregabalin | 12 | $1,300 |
| Propranolol Hcl ErPropranolol Hcl | 18 | $813 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 41 | $735 |
| Gabapentin | 34 | $252 |
| Risperidone | 14 | $221 |
| Sertraline Hcl | 20 | $138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $28 | $21,26720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 761 neurology providers in Massachusetts.
Other neurology in Brighton
- David WeinbergBrighton$231K
- Suja SadasivanBrighton$65K
- Christopher WrightBoston$2.5M
- Shivang JoshiWestborough$1.2M
- Egilius SpieringsWellesley Hills$680K
- Thomas ScammellBoston$617K
- Salvatore NapoliFoxboro$613K
- Alfred SandrockBoston$490K
- Joshua KatzWellesley$462K
- Guy BuckleBrookline$450K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.